Teva has no controlling shareholder. BlackRock holds about 5.5%, and Israeli insurers Harel, Phoenix and Menora hold 3% to 4% each. Who owns Teva, 2026.
Teva Pharmaceutical Industries, the world's largest generic drugmaker, has no controlling shareholder. BlackRock is its largest disclosed holder at about 5.5%, followed by Israeli insurers Harel, Phoenix and Menora, each holding roughly 3% to 4%. Teva is listed on the New York Stock Exchange as TEVA and in Tel Aviv, with a market value of roughly $35 billion to $42 billion during 2026.
Last updated: November 3, 2026.
Who Owns Teva Pharmaceutical Today?
| Field | Information |
|---|---|
| Legal company name | Teva Pharmaceutical Industries Ltd |
| Ultimate parent | None; widely held public company |
| Controlling shareholder | None |
| Largest disclosed holder | BlackRock, about 5.5% (June 30, 2026) |
| Public or private | Public |
| Stock exchange and ticker | NYSE: TEVA; also listed on the Tel Aviv Stock Exchange |
| Insider ownership | Below 1% |
| Ownership as of | June 30, 2026 for institutional holdings |
Founder, CEO, largest shareholder and controlling owner are different things at Teva. No founder family or executive controls it, and the largest holder is an index and asset manager, not an operator.
What Is Teva's Ownership History?
Teva's roots trace to Salomon, Levin and Elstein Ltd., founded in Jerusalem in 1901 and renamed Teva in the 1930s. In 1976 Teva merged with two other Israeli drug makers, Assia and Zori, to form the modern Teva Pharmaceutical Industries, with Assia executive Eli Hurvitz becoming the first CEO, according to Teva's corporate history. Teva listed in the United States in 1982, and by the 1980s the founding families had moved out of direct control in favor of professional management and a widening base of institutional shareholders.
That structure has become more diffuse. Teva made a large debt-financed acquisition in 2016, the purchase of Actavis Generics, and spent years reducing leverage, aiming for roughly 3x debt to EBITDA by late 2025 under a strategy it calls "Pivot to Growth." Teva also reached a nationwide opioid settlement of up to $4.25 billion, Reuters reported.
Who Are Teva's Major Shareholders?
| Holder | Approximate stake | Date reported |
|---|---|---|
| BlackRock | 5.5% | June 30, 2026 |
| Harel Insurance Investments and Financial Services | 4.1% | June 30, 2026 |
| Phoenix (Phoenix Holdings) | 3.7% | Q1 2026 |
| Menora Mivtachim | 3.4% | Q1 2026 |
Sources: Yahoo Finance holder data and SEC 13F filings as compiled by third-party trackers. Percentages shift each quarter, and the top 25 institutions together hold less than half the company, according to Simply Wall St. Institutions hold roughly 40% to 70% of Teva's shares depending on the data provider. Because no holder is anywhere near a controlling stake, Teva sits with Bezeq (since December 2025) and the Tel Aviv Stock Exchange among major Israeli-founded companies with no controlling shareholder; Teva has been in that position the longest.
What Other Companies Does Teva Control?
Teva's main acquired operating business is Actavis Generics, bought in 2016. Olam has not compiled a verified subsidiary list. In employment terms, Teva reported 4,613 U.S. employees at the end of 2025, the largest in Olam's sample of seven Israeli companies, covered in Sample of 7 Israeli Companies Shows 11,277 U.S. Employees.
How Much Is Teva Worth?
Teva's market capitalization was about $35 billion on April 2, 2026, and about $41 billion to $42 billion in late July and August 2026, according to market-data trackers. Teva's market value rose roughly 43% during 2025, from about $25 billion in January to about $36 billion in December. Market cap moves daily, so treat these as dated reference points.
What Are the Recent Ownership Developments?
- 2025: Teva shares rise sharply on the growth strategy and a reduced opioid-litigation overhang.
- 2026: BlackRock increases its position, with its holding reported at about 5.5% in June 2026.
- 2026: A Q2 2026 earnings summary describes Teva as transitioning to a direct NYSE listing; Olam has not verified the mechanics.
Frequently asked questions
Who is Teva's largest shareholder?
BlackRock, with about 5.5% as of June 30, 2026. Harel, Phoenix and Menora Mivtachim each hold roughly 3% to 4%.
Is Teva Israeli-owned?
Teva is Israeli-founded and headquartered, but widely held. No single investor controls it, and most of its shares are held by global and Israeli institutions.
Has Teva always lacked a controlling shareholder?
Largely, since the 1980s. The founding families behind the 1976 merger moved out of direct control as the company listed in the United States and institutions took over.
What was Teva's opioid settlement?
Teva agreed to a nationwide settlement of up to $4.25 billion, paid over 13 years and including naloxone supply, to resolve U.S. lawsuits over its role in the opioid crisis, without admitting wrongdoing.
Related Olam Coverage
- Sample of 7 Israeli Companies Shows 11,277 U.S. Employees
- Who Owns the Tel Aviv Stock Exchange?
- Who Owns Israel's Telecoms?
- Israeli Health and Biotech
Sources and Methodology
Holdings come from SEC 13F filings and market-data trackers, with dates shown. Olam does not infer ownership from nationality, surname or history.
Teva, corporate history; Wikipedia, Teva Pharmaceuticals; Yahoo Finance, TEVA holders; 13F tracker, TEVA institutional holders (Q1 2026); Simply Wall St, Teva ownership; Public.com, Teva market cap; Reuters, Teva opioid settlement; Texas Attorney General, settlement terms.
How we report: Olam stories draw on public filings, company disclosures and named sources, checked by our editors. Read our methodology · Corrections
